Recruitment of ethnic minorities into cancer clinical trials: experience from the front linesSYMONDS, R. P; LORD, K; MITCHELL, A. J et al.British journal of cancer. 2012, Vol 107, Num 7, pp 1017-1021, issn 0007-0920, 5 p.Article

Twenty Years Post-NIH Revitalization Act: Enhancing Minority Participation in Clinical Trials (EMPaCT): Laying the Groundwork for Improving Minority Clinical Trial Accrual: Renewing the Case for Enhancing Minority Participation in Cancer Clinical TrialsCHEN, Moon S; LARA, Primo N; DANG, Julie H. T et al.Cancer. 2014, Vol 120, Num 7, pp 1091-1096, issn 0008-543X, 6 p., SUPArticle

The impact of socioeconomic status on access to cancer clinical trialsSHARROCKS, K; SPICER, J; CAMIDGE, D. R et al.British journal of cancer. 2014, Vol 111, Num 9, pp 1684-1687, issn 0007-0920, 4 p.Article

Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-pointsWASON, James M. S; MANDER, Adrian P; EISEN, Tim G et al.European journal of cancer (1990). 2011, Vol 47, Num 7, pp 983-989, issn 0959-8049, 7 p.Article

A randomised controlled study of an audiovisual patient information intervention on informed consent and recruitment to cancer clinical trialsHUTCHISON, C; COWAN, C; MCMAHON, T et al.British journal of cancer. 2007, Vol 97, Num 6, pp 705-711, issn 0007-0920, 7 p.Article

The Changing Face of Phase 1 Cancer Clinical Trials : New Challenges in Study RequirementsCRAFT, Barbara S; KURZROCK, Razelle; XIUDONG LEI et al.Cancer. 2009, Vol 115, Num 8, pp 1592-1597, issn 0008-543X, 6 p.Article

Knowledge and understanding among cancer patients consenting to participate in clinical trialsBERGENMAR, Mia; MOLIN, Clementine; WILKING, Nils et al.European journal of cancer (1990). 2008, Vol 44, Num 17, pp 2627-2633, issn 0959-8049, 7 p.Article

Inclusion of Minorities and Women in Cancer Clinical Trials, a Decade Later: Have We Improved?KWIATKOWSKI, Kat; COE, Kathryn; BAILAR, John C et al.Cancer. 2013, Vol 119, Num 16, pp 2956-2963, issn 0008-543X, 8 p.Article

Overcoming Barriers to Cancer Clinical Trial Accrual : Impact of a Mass Media CampaignUMUTYAN, Ari; CHIECHI, Christine; BECKETT, Laurel A et al.Cancer. 2008, Vol 112, Num 1, pp 212-219, issn 0008-543X, 8 p.Article

Mechanisms of the Anti-Cancer and Anti-Inflammatory Actions of Vitamin DKRISHNAN, Aruna V; FELDMAN, David.Annual review of pharmacology and toxicology (Print). 2011, Vol 51, pp 311-336, issn 0362-1642, 26 p.Article

Exploring websites on cancer clinical trials : An empirical reviewSIMON, Christian; HEGEDUS, Sarah.Contemporary clinical trials. 2005, Vol 26, Num 5, pp 530-533, issn 1551-7144, 4 p.Article

Participation in Cancer Clinical Trials as Viewed by Chinese Patients and Their FamiliesLI, Jun-Ying; YU, Chun-Hua; YU JIANG et al.Oncology. 2010, Vol 79, Num 5-6, pp 343-348, issn 0030-2414, 6 p.Article

Clinical impact of visceral pleural, lymphovascular and perineural invasion in completely resected non-small cell lung cancerYILMAZ, Aydin; SAHIN DUYAR, Sezgi; CAKIR, Ebru et al.European journal of cardio-thoracic surgery. 2011, Vol 40, Num 3, pp 664-670, issn 1010-7940, 7 p.Article

Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II studyBURSTEIN, Harold J; DEMETRI, George D; MUELLER, Elisabetta et al.Breast cancer research and treatment. 2003, Vol 79, Num 3, pp 391-397, issn 0167-6806, 7 p.Article

On the use of pharmacogenetics in cancer treatment and clinical trialsROBERT, Jacques; LE MORVAN, Valérie; GIOVANNETTI, Elisa et al.European journal of cancer (1990). 2014, Vol 50, Num 15, pp 2532-2543, issn 0959-8049, 12 p.Article

High-throughput techniques in breast cancer : A clinical perspectiveESPINOSA, Enrique; REDONDO, Andrés; FRESNO VARA, Juan Angel et al.European journal of cancer (1990). 2006, Vol 42, Num 5, pp 598-607, issn 0959-8049, 10 p.Article

Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patientsEDIEBAH, D. E; COENS, C; WEIS, J et al.Annals of oncology. 2013, Vol 24, Num 1, pp 231-237, issn 0923-7534, 7 p.Article

Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trialsBORAD, Mitesh J; SOMAN, Arundhati D; VON HOFF, Daniel D et al.Investigational new drugs. 2013, Vol 31, Num 4, pp 1056-1065, issn 0167-6997, 10 p.Article

On the maximum total sample size of a group sequential test about bivariate binomial proportionsYU, Jihnhee; KEPNER, James L.Statistics & probability letters. 2011, Vol 81, Num 7, pp 829-835, issn 0167-7152, 7 p.Article

Lymphedema in women with breast cancer : characteristics of patients screened for a randomized trialDAYES, Ian S; LEVINE, Mark N; JULIAN, J. A et al.Breast cancer research and treatment. 2008, Vol 110, Num 2, pp 337-342, issn 0167-6806, 6 p.Article

The attitudes of oncology physicians and nurses toward phase I, II, and III cancer clinical trialsJIE ZHANG; HONG ZHANG; CHUNHUA YU et al.Contemporary clinical trials. 2011, Vol 32, Num 5, pp 649-653, issn 1551-7144, 5 p.Article

Unifying CRM and EWOC designs for phase I cancer clinical trialsCHU, Pei-Ling; YONG LIN; SHIH, Weichung Joe et al.Journal of statistical planning and inference. 2009, Vol 139, Num 3, pp 1146-1163, issn 0378-3758, 18 p.Article

A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancerKAUFMAN, Donald S; CARDUCCI, Michael A; KUZEL, Tim M et al.Urologic oncology. 2004, Vol 22, Num 5, pp 393-397, issn 1078-1439, 5 p.Article

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumorsSTINCHCOMBE, Thomas E; SOCINSKI, Mark A; DEES, E. Claire et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 5, pp 759-766, issn 0344-5704, 8 p.Article

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: Phase IB trialDRAGOVICH, Tomislav; HUBERMAN, Mark; VON HOFF, Daniel D et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 2, pp 295-303, issn 0344-5704, 9 p.Article